School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin 124001, China.
Department of Orthopedic Surgery, The Third People's Hospital of Shenzhen, Shenzhen 518000, China.
Mediators Inflamm. 2021 Oct 21;2021:3456629. doi: 10.1155/2021/3456629. eCollection 2021.
Inflammatory markers are associated with tumor genesis and progression, but their prognostic significance in osteosarcoma remains unclear. Therefore, we discussed the prognostic value of related inflammatory markers in osteosarcoma through a meta-analysis and systematic review. These inflammatory markers include C-reactive protein (CRP), neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR), and Glasgow prognostic score (GPS).
The Chinese National Knowledge Infrastructure (CNKI), Wanfang, Chinese Scientific Journals (VIP), PubMed, Embase, and Cochrane libraries were searched. The design of meta-analysis was made based on the PICOS (population, intervention/exposure, control, outcomes, and study design) principles, and STATA 15.1 was used to analyze the data. The Newcastle-Ottawa scale (NOS) was used to assess the quality of included studies. Hazard ratios (HRs) for overall survival (OS) and disease-specific survival (DPS) were extracted for the investigation of the prognostic value of inflammatory markers.
Twelve researches with 2162 osteosarcoma patients were included in total. The pooled results showed that elevated NLR, CRP, and GPS are all greatly related to shortening of OS among patients with osteosarcoma (HR = 1.68, = 0.007, 95% CI: 1.15-2.45; HR = 1.96, = 0.002, 95% CI: 1.28-3.00; HR = 2.54, < 0.0001, 95% CI: 1.95-3.31, respectively), and CRP level is significantly associated with shortening of DPS among patients with osteosarcoma (HR = 2.76, 95% CI:2.01-3.80, < 0.0001), additionally. However, the correlation between LMR or PLR and the prognosis of osteosarcoma is not statistically significant (HR = 0.60, 95% CI: 0.30-1.18, = 0.138; HR = 1.13, 95% CI: 0.85-1.49, = 0.405, respectively). The outcomes of subgroup analysis to NLR and CRP suggested that histology, ethnicity, metastasis, and sample size all have an impact on its prognosis of patients with osteosarcoma.
Worsened prognosis may be related to high levels of NLR, CRP, and GPS before treatment rather than LMR or PLR, which can provide the basis for clinicians to judge the outcomes of prognosis. . PROSPERO (CRD42021249954), https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=249954.
炎症标志物与肿瘤的发生和进展有关,但它们在骨肉瘤中的预后意义尚不清楚。因此,我们通过荟萃分析和系统评价讨论了相关炎症标志物在骨肉瘤中的预后价值。这些炎症标志物包括 C 反应蛋白(CRP)、中性粒细胞与淋巴细胞比值(NLR)、淋巴细胞与单核细胞比值(LMR)、血小板与淋巴细胞比值(PLR)和格拉斯哥预后评分(GPS)。
检索中国知网(CNKI)、万方、中国科学期刊(VIP)、PubMed、Embase 和 Cochrane 图书馆。基于 PICOS(人群、干预/暴露、对照、结局和研究设计)原则设计荟萃分析,并使用 STATA 15.1 分析数据。采用纽卡斯尔-渥太华量表(NOS)评估纳入研究的质量。提取总生存(OS)和疾病特异性生存(DPS)的风险比(HRs),以探讨炎症标志物的预后价值。
共纳入 12 项研究,共 2162 例骨肉瘤患者。汇总结果表明,升高的 NLR、CRP 和 GPS 均与骨肉瘤患者 OS 缩短显著相关(HR=1.68, =0.007,95%CI:1.15-2.45;HR=1.96, =0.002,95%CI:1.28-3.00;HR=2.54, <0.0001,95%CI:1.95-3.31,分别),且 CRP 水平与骨肉瘤患者 DPS 缩短显著相关(HR=2.76,95%CI:2.01-3.80, <0.0001)。此外,LMR 或 PLR 与骨肉瘤的预后无显著相关性(HR=0.60,95%CI:0.30-1.18, =0.138;HR=1.13,95%CI:0.85-1.49, =0.405,分别)。NLR 和 CRP 的亚组分析结果表明,组织学、种族、转移和样本量均对骨肉瘤患者的预后有影响。
治疗前 NLR、CRP 和 GPS 水平升高可能与预后不良有关,而 LMR 或 PLR 则与预后无关,可为临床医生判断预后结局提供依据。. PROSPERO(CRD42021249954),https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=249954。